Leaps by Bayer

Temporary respite or reflection of a stabilizing sector?

Developers of programmable CAR T therapies and human-compatible organs for transplantation garner nine-figure fundings

Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona

As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public

Public offerings by Akero, BridgeBio, RegenxBio, Apogee, plus PIPEs for Ventyx and BiomX-Adaptive Phage union

Checkpoint inhibitor against HHLA2-KIR3DL3 axis might work where PD-1 blockers don’t

The island nation has caught the interest of international investors and pharmas. Will this be the moment its biotech accelerates?

Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more

Plus: Peterson joins Exelixis, Eckhardt expands role at Bayer and updates from Alpine, Neuron23, Ajax

Former analyst arrived at venture firm in May after leaving EQRx